Candel Therapeutics’ (CADL) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Candel Therapeutics (NASDAQ:CADL) in a research report sent to investors on Monday morning,Benzinga reports. They currently have a $11.00 price objective on the stock. HC Wainwright also issued estimates for Candel Therapeutics’ Q4 2024 earnings at ($0.30) EPS, FY2024 earnings at ($1.65) EPS and FY2025 earnings at $0.15 EPS.

Candel Therapeutics Stock Down 0.3 %

CADL opened at $3.98 on Monday. The company has a market cap of $129.25 million, a PE ratio of -2.30 and a beta of -0.88. The business has a 50 day moving average price of $5.90 and a two-hundred day moving average price of $6.67. Candel Therapeutics has a 52 week low of $0.77 and a 52 week high of $14.30. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 1.66.

Insiders Place Their Bets

In other news, major shareholder Estuardo Aguilar-Cordova sold 15,000 shares of the firm’s stock in a transaction dated Friday, October 11th. The stock was sold at an average price of $6.05, for a total transaction of $90,750.00. Following the completion of the sale, the insider now directly owns 944,873 shares in the company, valued at $5,716,481.65. This trade represents a 1.56 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold a total of 31,800 shares of company stock valued at $193,380 in the last quarter. 41.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Candel Therapeutics

A number of institutional investors have recently added to or reduced their stakes in CADL. Bank of New York Mellon Corp acquired a new position in shares of Candel Therapeutics in the second quarter worth $338,000. Rhumbline Advisers bought a new stake in Candel Therapeutics in the second quarter worth $143,000. Point72 DIFC Ltd bought a new stake in Candel Therapeutics in the second quarter worth $31,000. Cubist Systematic Strategies LLC bought a new stake in Candel Therapeutics in the second quarter worth $162,000. Finally, FMR LLC bought a new stake in Candel Therapeutics in the third quarter worth $46,000. 13.93% of the stock is currently owned by institutional investors and hedge funds.

About Candel Therapeutics

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.